Professor Richard Wilson

  • Professor of Gastro-Intestinal Oncology (Translational Research Centre)

Biography

Richard Wilson graduated from Queen’s University Belfast in 1984 and then worked in N. Ireland and Scotland as a junior doctor in surgery which included three years of colorectal cancer laboratory research in QUB. He then retrained in clinical oncology before undertaking a post-CCT Fellowship in the National Cancer Institute in the USA in medical oncology and drug development.

He was appointed in 2001 as a Consultant and Senior Lecturer in Belfast City Hospital and QUB. He set up the first early phase cancer clinical trials programme on the island of Ireland, and was the first Clinical Director of the N. Ireland Cancer Trials Network.

His main interests are in gastrointestinal cancer (particularly colorectal cancer but also small bowel and anal cancer and peritoneal malignancies), in drug development, biomarkers, stratified medicine and early and late phase clinical trials.

His work includes cancer biology, translational and clinical research. After 17 years back in Belfast, he moved to the Institute of Cancer Sciences in the University of Glasgow and the Beatson West of Scotland Cancer Centre in early 2019 where he is Professor of Gastrointestinal Oncology and an Honorary Consultant in Medical Oncology.

Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2016 | 2015 | 2014
Number of items: 34.

2019

Joharatnam-Hogan, N. et al. (2019) Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology, 4(11), pp. 854-862. (doi: 10.1016/S2468-1253(19)30289-4) (PMID:31477558)

Salvucci, M. et al. (2019) A machine learning platform to optimize the translation of personalized network models to the clinic. JCO Clinical Cancer Informatics(3), pp. 1-17. (doi: 10.1200/CCI.18.00056) (PMID:30995124)

2018

Arkenau, H.-T. et al. (2018) An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer, 103, pp. 17-23. (doi: 10.1016/j.ejca.2018.07.134) (PMID:30196106)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29(9), pp. 1918-1925. (doi: 10.1093/annonc/mdy245) (PMID:30016392) (PMCID:PMC6158767)

Cross, W. et al. (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2(10), pp. 1661-1672. (doi: 10.1038/s41559-018-0642-z) (PMID:30177804) (PMCID:PMC6152905)

Allen, W. L. et al. (2018) Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy. JCO Precision Oncology(2), pp. 1-15. (doi: 10.1200/PO.17.00241) (PMID:30088816) (PMCID:PMC6040635)

Woodcock, V. K. et al. (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118(6), pp. 770-776. (doi: 10.1038/bjc.2017.484) (PMID:29438361) (PMCID:PMC5877436)

Adams, R. et al. (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3(3), pp. 162-171. (doi: 10.1016/S2468-1253(17)30394-1) (PMID:29254887) (PMCID:PMC6125825)

2017

Lawler, M. et al. (2017) Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 67(1), pp. 179-193. (doi: 10.1136/gutjnl-2017-315333) (PMID:29233930) (PMCID:PMC5754857)

Schrock, A. B. et al. (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncology, 3(11), p. 1546. (doi: 10.1001/jamaoncol.2017.1051) (PMID:28617917) (PMCID:PMC5710195)

Alvi, M. A., Wilson, R. H. and Salto-Tellez, M. (2017) Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 117(9), pp. 1255-1257. (doi: 10.1038/bjc.2017.321) (PMID:28934760) (PMCID:PMC5672935)

Alderdice, M. et al. (2017) Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 30(9), pp. 1287-1298. (doi: 10.1038/modpathol.2017.47) (PMID:28621318)

Alvi, M. A. et al. (2017) Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 117(2), pp. 203-209. (doi: 10.1038/bjc.2017.168) (PMID:28595259) (PMCID:PMC5520517)

Salvucci, M. et al. (2017) A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23(5), pp. 1200-1212. (doi: 10.1158/1078-0432.CCR-16-1084) (PMID:27649552)

2016

Coyle, C. et al. (2016) ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 51, pp. 56-64. (doi: 10.1016/j.cct.2016.10.004) (PMID:27777129) (PMCID:PMC5127874)

Jamieson, D. et al. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi: 10.1016/j.ejca.2016.08.026) (PMID:27693888)

Lindner, A. U. et al. (2016) BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 66(12), pp. 2141-2148. (doi: 10.1136/gutjnl-2016-312287) (PMID:27663504)

Graham, D. M., Coyle, V. M., Kennedy, R. D. and Wilson, R. H. (2016) Molecular subtypes and personalized therapy in metastatic colorectal cancer. Current Colorectal Cancer Reports, 12(3), pp. 141-150. (doi: 10.1007/s11888-016-0312-y) (PMID:27340376) (PMCID:PMC4879165)

ORIGIN Trial Investigators, (2016) Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care, 39(5), pp. 709-716. (doi: 10.2337/dc15-1676) (PMID:26681720)

Lawler, M. et al. (2016) Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 122(5), pp. 664-673. (doi: 10.1002/cncr.29814) (PMID:26695702) (PMCID:PMC4864440)

Pitsiladis, Y. P. et al. (2016) Athlome Project Consortium: a concerted effort to discover genomic and other “omic” markers of athletic performance. Physiological Genomics, 48(3), pp. 183-190. (doi: 10.1152/physiolgenomics.00105.2015)

Dunne, P.D. et al. (2016) EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clinical Cancer Research, 22(1), pp. 230-242. (doi: 10.1158/1078-0432.CCR-15-0603) (PMID:26283684) (PMCID:PMC4694030)

2015

Lawler, M., Kaplan, R., Wilson, R.H. and Maughan, T. (2015) Changing the paradigm - multistage multiarm randomized trials and stratified cancer medicine. Oncologist, 20(8), pp. 849-851. (doi: 10.1634/theoncologist.2015-0014) (PMID:26070918) (PMCID:PMC4524758)

Alvi, M. A. et al. (2015) Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 6(25), pp. 20863-20874. (doi: 10.18632/oncotarget.4576) (PMID:26315110) (PMCID:PMC4673235)

Graham, D.M., Turkington, R.C., Salto-Tellez, M., Coyle, V.M. and Wilson, R.H. (2015) RE: Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. Journal of the National Cancer Institute, 107(5), djv055. (doi: 10.1093/jnci/djv055) (PMID:25758031)

Bogaerts, J. et al. (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. European Journal of Cancer, 51(3), pp. 271-281. (doi: 10.1016/j.ejca.2014.10.027) (PMID:25542058)

Wardle, S. L., Bailey, M. E. , Kilikevicius, A., Malkova, D. , Wilson, R. H. , Venckunas, T. and Moran, C. (2015) Plasma microRNA levels differ between endurance and strength athletes. PLoS ONE, 10(4), e0122107. (doi: 10.1371/journal.pone.0122107) (PMID:25881132) (PMCID:PMC4400105)

2014

Moreno Garcia, V. et al. (2014) Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. Clinical Cancer Research, 20(22), pp. 5663-5671. (doi: 10.1158/1078-0432.CCR-14-0719)

Andreyev, J. et al. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, 15(10), e447-e460. (doi: 10.1016/S1470-2045(14)70006-3) (PMID:25186048)

Wasan, H. et al. (2014) Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15(6), pp. 631-639. (doi: 10.1016/S1470-2045(14)70106-8) (PMID:24703531) (PMCID:PMC4012566)

Maughan, T.S. et al. (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110(9), pp. 2178-2186. (doi: 10.1038/bjc.2014.182) (PMID:24743706) (PMCID:PMC4007241)

Turkington, R.C., Purcell, C., James, C.R., Millar, J., Napier, E., Law, D., Gallagher, R., Morris, M., Wilson, R.H. and Eatock, M.M. (2014) A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. Investigational New Drugs, 32(2), pp. 250-260. (doi: 10.1007/s10637-013-9970-7) (PMID:23665866)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

Jones, C., Badger, S. A., Stevenson, M., Diamond, T., McKie, L. D., Taylor, M. A., Wilson, R. H. and Lynch, T. B. (2014) PET-CT as a predictor of outcome in resectable colorectal liver metastases. European Journal of Gastroenterology and Hepatology, 26(4), pp. 466-472. (doi: 10.1097/MEG.0000000000000036) (PMID:24445726)

This list was generated on Thu Sep 17 09:44:50 2020 BST.
Jump to: Articles
Number of items: 34.

Articles

Joharatnam-Hogan, N. et al. (2019) Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology, 4(11), pp. 854-862. (doi: 10.1016/S2468-1253(19)30289-4) (PMID:31477558)

Salvucci, M. et al. (2019) A machine learning platform to optimize the translation of personalized network models to the clinic. JCO Clinical Cancer Informatics(3), pp. 1-17. (doi: 10.1200/CCI.18.00056) (PMID:30995124)

Arkenau, H.-T. et al. (2018) An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer, 103, pp. 17-23. (doi: 10.1016/j.ejca.2018.07.134) (PMID:30196106)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29(9), pp. 1918-1925. (doi: 10.1093/annonc/mdy245) (PMID:30016392) (PMCID:PMC6158767)

Cross, W. et al. (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2(10), pp. 1661-1672. (doi: 10.1038/s41559-018-0642-z) (PMID:30177804) (PMCID:PMC6152905)

Allen, W. L. et al. (2018) Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy. JCO Precision Oncology(2), pp. 1-15. (doi: 10.1200/PO.17.00241) (PMID:30088816) (PMCID:PMC6040635)

Woodcock, V. K. et al. (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118(6), pp. 770-776. (doi: 10.1038/bjc.2017.484) (PMID:29438361) (PMCID:PMC5877436)

Adams, R. et al. (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3(3), pp. 162-171. (doi: 10.1016/S2468-1253(17)30394-1) (PMID:29254887) (PMCID:PMC6125825)

Lawler, M. et al. (2017) Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 67(1), pp. 179-193. (doi: 10.1136/gutjnl-2017-315333) (PMID:29233930) (PMCID:PMC5754857)

Schrock, A. B. et al. (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncology, 3(11), p. 1546. (doi: 10.1001/jamaoncol.2017.1051) (PMID:28617917) (PMCID:PMC5710195)

Alvi, M. A., Wilson, R. H. and Salto-Tellez, M. (2017) Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 117(9), pp. 1255-1257. (doi: 10.1038/bjc.2017.321) (PMID:28934760) (PMCID:PMC5672935)

Alderdice, M. et al. (2017) Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 30(9), pp. 1287-1298. (doi: 10.1038/modpathol.2017.47) (PMID:28621318)

Alvi, M. A. et al. (2017) Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 117(2), pp. 203-209. (doi: 10.1038/bjc.2017.168) (PMID:28595259) (PMCID:PMC5520517)

Salvucci, M. et al. (2017) A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23(5), pp. 1200-1212. (doi: 10.1158/1078-0432.CCR-16-1084) (PMID:27649552)

Coyle, C. et al. (2016) ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 51, pp. 56-64. (doi: 10.1016/j.cct.2016.10.004) (PMID:27777129) (PMCID:PMC5127874)

Jamieson, D. et al. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi: 10.1016/j.ejca.2016.08.026) (PMID:27693888)

Lindner, A. U. et al. (2016) BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 66(12), pp. 2141-2148. (doi: 10.1136/gutjnl-2016-312287) (PMID:27663504)

Graham, D. M., Coyle, V. M., Kennedy, R. D. and Wilson, R. H. (2016) Molecular subtypes and personalized therapy in metastatic colorectal cancer. Current Colorectal Cancer Reports, 12(3), pp. 141-150. (doi: 10.1007/s11888-016-0312-y) (PMID:27340376) (PMCID:PMC4879165)

ORIGIN Trial Investigators, (2016) Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care, 39(5), pp. 709-716. (doi: 10.2337/dc15-1676) (PMID:26681720)

Lawler, M. et al. (2016) Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 122(5), pp. 664-673. (doi: 10.1002/cncr.29814) (PMID:26695702) (PMCID:PMC4864440)

Pitsiladis, Y. P. et al. (2016) Athlome Project Consortium: a concerted effort to discover genomic and other “omic” markers of athletic performance. Physiological Genomics, 48(3), pp. 183-190. (doi: 10.1152/physiolgenomics.00105.2015)

Dunne, P.D. et al. (2016) EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clinical Cancer Research, 22(1), pp. 230-242. (doi: 10.1158/1078-0432.CCR-15-0603) (PMID:26283684) (PMCID:PMC4694030)

Lawler, M., Kaplan, R., Wilson, R.H. and Maughan, T. (2015) Changing the paradigm - multistage multiarm randomized trials and stratified cancer medicine. Oncologist, 20(8), pp. 849-851. (doi: 10.1634/theoncologist.2015-0014) (PMID:26070918) (PMCID:PMC4524758)

Alvi, M. A. et al. (2015) Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 6(25), pp. 20863-20874. (doi: 10.18632/oncotarget.4576) (PMID:26315110) (PMCID:PMC4673235)

Graham, D.M., Turkington, R.C., Salto-Tellez, M., Coyle, V.M. and Wilson, R.H. (2015) RE: Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. Journal of the National Cancer Institute, 107(5), djv055. (doi: 10.1093/jnci/djv055) (PMID:25758031)

Bogaerts, J. et al. (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. European Journal of Cancer, 51(3), pp. 271-281. (doi: 10.1016/j.ejca.2014.10.027) (PMID:25542058)

Wardle, S. L., Bailey, M. E. , Kilikevicius, A., Malkova, D. , Wilson, R. H. , Venckunas, T. and Moran, C. (2015) Plasma microRNA levels differ between endurance and strength athletes. PLoS ONE, 10(4), e0122107. (doi: 10.1371/journal.pone.0122107) (PMID:25881132) (PMCID:PMC4400105)

Moreno Garcia, V. et al. (2014) Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. Clinical Cancer Research, 20(22), pp. 5663-5671. (doi: 10.1158/1078-0432.CCR-14-0719)

Andreyev, J. et al. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, 15(10), e447-e460. (doi: 10.1016/S1470-2045(14)70006-3) (PMID:25186048)

Wasan, H. et al. (2014) Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15(6), pp. 631-639. (doi: 10.1016/S1470-2045(14)70106-8) (PMID:24703531) (PMCID:PMC4012566)

Maughan, T.S. et al. (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110(9), pp. 2178-2186. (doi: 10.1038/bjc.2014.182) (PMID:24743706) (PMCID:PMC4007241)

Turkington, R.C., Purcell, C., James, C.R., Millar, J., Napier, E., Law, D., Gallagher, R., Morris, M., Wilson, R.H. and Eatock, M.M. (2014) A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. Investigational New Drugs, 32(2), pp. 250-260. (doi: 10.1007/s10637-013-9970-7) (PMID:23665866)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

Jones, C., Badger, S. A., Stevenson, M., Diamond, T., McKie, L. D., Taylor, M. A., Wilson, R. H. and Lynch, T. B. (2014) PET-CT as a predictor of outcome in resectable colorectal liver metastases. European Journal of Gastroenterology and Hepatology, 26(4), pp. 466-472. (doi: 10.1097/MEG.0000000000000036) (PMID:24445726)

This list was generated on Thu Sep 17 09:44:50 2020 BST.